Medicare announces lower prices for 15 drugs including Ozempic, Wegovy

CMS announced negotiated Medicare prices for 15 drugs effective 2027 under the Inflation Reduction Act, cutting 30-day prices such as Ozempic/Rybelsus/Wegovy to $274 (list $959) and Trelegy Ellipta to $175 (list $654). The drugs represented roughly $42.5 billion in Part D spending in 2024 for about 5.3 million beneficiaries; CMS projects ~ $12 billion in Medicare savings and ~$685 million in beneficiary out-of-pocket savings, with average net spending reductions of 36% and individual cuts (e.g., Calquence, Ofev, Ibrance) exceeding $4,000 — a material revenue headwind for affected pharma companies.

Analysis

Market structure: The Medicare negotiations materially reallocate pricing power from brand pharma to payers for the 15 drugs listed (effective 2027), with projected net spending cuts ~36% vs prior 22% round. Direct losers by revenue exposure: AZN (Calquence), PFE (Ibrance), ABBV, GSK and AMGN where Medicare share >10% of U.S. sales; winners are downstream payers (Part D plans, PBMs) and beneficiaries via lower OOP costs. Competitive dynamics favor manufacturers with scale/GLP-1 franchises (NVO) that can grow volume to offset price erosion; niche oncology/ specialty franchises with limited elastic demand will suffer disproportionate margin pressure.

Risk assessment: Tail risks include accelerated policy expansion (Part B inclusion or broader price-setting), successful legal challenges by manufacturers, or larger-than-expected rebate shifting that hits PBM economics; each could move valuation +/-20-40% for mid-cap biopharma in stressed scenarios. Timeline: immediate market repricing (days–weeks) around earnings and CMS implementation details; realized revenue/earnings impact concentrated in 2027–2029 fiscal years. Hidden dependencies: list vs net price and rebate mechanics—PBM/insurer pass-through and manufacturer rebate reserves may create lumpy earnings adjustments in 2026–2028.

Trade implications: Tactical shorts: 1–2% notional short on AZN and PFE equities into next 12–18 months due to >$4k/mo per-patient cuts and concentrated oncology exposure; buy 9–15 month puts (10–20% OTM) to cap risk. Relative value: pair short AZN or PFE vs long large PBM/insurer exposure (e.g., CVS, UNH) to capture spread compression if net plan costs fall. For NVO consider small asymmetric long via call spread 12–24 month to play volume offset in GLP-1s while limiting downside.

Contrarian angles: Consensus overweights headline downside for GLP-1 maker NVO — Medicare covers older demographics where uptake is smaller today; a negotiated $274 price could materially expand senior uptake, driving incremental volumes that partially offset price loss. Market may over-penalize large-cap diversified pharmas where 2027 cuts apply only to Part D formulations; identify mispricings where >15% forward EPS is already discounted but actual Medicare share implies <5–10% revenue hit. Monitor CMS final rule (next 6–12 months) and company-specific gross-to-net disclosures for entry opportunities.

Key Decisions for Investors

• Establish a 1.5–2.5% notional short position in AZN for 12–18 months, financed by selling 9–12 month covered calls or buying 12-month puts 10–20% OTM; target capture if AZN reports >10% downside to consensus EPS on 2027 guidance revisions.
• Initiate a 1–2% long in UNH or CVS (equal-weight) as a hedge against lower Part D net costs; hold 6–18 months to benefit from potential margin tailwind if plan costs drop >5% and PBM spread improves.
• Buy a 12–24 month call spread on NVO (buy ATM, sell +25% strike) sized 0.5–1% notional to play GLP-1 volume upside at limited cost; exit if Medicare-specific volume for seniors fails to grow by >15% year-over-year in 2027.
• Purchase 6–12 month puts on PFE (1% portfolio notional) or add to existing hedges ahead of next quarterly earnings if company does not quantify 2027 Part D exposure; cover if implied vol >40% and downside <15% realized.
• Reduce pure oncology/specialty small-cap exposure by 25–40% across the next 3 months and redeploy to healthcare services and defensive funds if CMS expands negotiation scope beyond Part D in 2028 (trigger: CMS announcement within 6 months).